Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Tenaya Therapeutics, Inc. director June Lee received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The options will vest in full on May 28, 2027, or earlier on the day immediately before the next annual stockholder meeting after the grant date, as long as Lee continues as a service provider to the company. The options expire on May 27, 2036, and following this grant Lee holds 120,000 options in total.
Tenaya Therapeutics, Inc. reported that director Amy L. Burroughs received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share, were granted as compensation under the company’s Amended and Restated 2021 Equity Incentive Plan, and vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant date, if sooner. The options expire on May 27, 2036, and this filing does not reflect any open‑market buying or selling of Tenaya shares.
Tenaya Therapeutics, Inc. amended and restated its 2021 Equity Incentive Plan after stockholder approval at the May 27, 2026 annual meeting. The plan now includes a one-time increase of approximately 3% of outstanding shares, adding 6,509,966 shares reserved for equity awards, and revises the annual evergreen provision to a 4% of outstanding shares formula without the prior 4 million share cap. Stockholders also elected three Class II directors to terms ending at the 2029 annual meeting and ratified Deloitte & Touche LLP as independent auditor for the 2026 fiscal year.
Tenaya Therapeutics Chief Executive Officer Ali Faraz reported an open-market sale of 3,390 shares of common stock at $0.7934 per share on May 18, 2026. According to the footnotes, the shares were sold to cover tax withholding obligations related to vesting restricted stock units awarded on February 6, 2025.
After this transaction, Faraz directly holds 440,014 shares of Tenaya Therapeutics common stock. The holding figure includes 321,581 shares that will be issued upon future vesting of restricted stock units, underscoring that the reported sale is tied to tax obligations rather than a reduction of long-term equity awards.
Tenaya Therapeutics Chief Medical Officer Tingley Whittemore reported a small share sale primarily tied to taxes. On the reported date, Whittemore sold 3,121 shares of common stock at $0.7936 per share to cover tax withholding obligations related to vesting restricted stock units awarded on January 24, 2025.
After this transaction, Whittemore held 215,497 shares of Tenaya Therapeutics common stock directly, which includes 112,919 shares that will be issued upon future vesting of restricted stock units. The filing reflects a routine, tax-driven disposition rather than a large change in overall ownership.
Tenaya Therapeutics, Inc. SVP of Finance Tomohiro Higa reported an open-market sale of 1,485 shares of common stock on May 18, 2026 at an average price of $0.7932 per share. According to the disclosure, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on August 15, 2024.
After this transaction, Higa directly holds 118,267 shares of Tenaya common stock. This figure includes 67,938 shares that will be issued to him upon future vesting of restricted stock units, indicating that the sale represents a small portion of his overall equity exposure.
Tenaya Therapeutics reported a smaller quarterly loss while adding its first collaboration revenue and a major new research partnership. For the three months ended March 31, 2026, net loss was $19.3 million, improving from $26.9 million a year earlier as research and development and general and administrative expenses fell about 30% and 16%, respectively. The company ended the quarter with $80.9 million in cash and cash equivalents and believes this will fund operations for at least twelve months. Tenaya recorded $0.2 million of collaboration revenue and set up $10.4 million of contract liabilities tied mainly to a new multi-target cardiovascular discovery collaboration with Alnylam, which includes a fixed $10.0 million upfront platform access fee and potential milestones of up to $1.1 billion. Management continues to focus spending on its three lead programs TN-201, TN-401 and TN-301 while progressing early-stage pipeline and maintaining one operating segment.
Tenaya Therapeutics reported first quarter 2026 results and a broad pipeline update. Collaboration revenue was $225,000, total operating expenses were $20.3 million, and net loss narrowed to $19.3 million, or $0.09 per share, compared with a $26.9 million loss a year earlier.
Cash and cash equivalents were $80.9 million as of March 31, 2026, and together with a $10.0 million upfront payment from a new Alnylam collaboration are expected to fund operations into the second half of 2027. The company highlighted upcoming 2026 data readouts for gene therapies TN-201 and TN-401, preclinical progress for TN-301, and design-stage work on gene editing candidate TN-501.
Tenaya Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on May 27, 2026. The agenda includes electing three Class II directors to serve until 2029, ratifying Deloitte & Touche LLP as auditor for the year ending December 31, 2026, and approving changes to the 2021 Equity Incentive Plan.
The amended and restated plan would add 6,509,966 shares of common stock, described as approximately 3% of outstanding shares, to the shares reserved for issuance and remove the 4 million share annual limit from the plan’s 4% “evergreen” increase. The board currently has eight members, seven deemed independent, and recommends voting “FOR” all three proposals.